# Patrick Hwu

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/patrick-hwu/

## Facts

| Field | Value |
| --- | --- |
| Citations | 34,141 |
| Field | CAR-T cell therapy research |
| h-index | 71 |
| i10-index | 174 |
| Last Known Institution | Moffitt Cancer Center |
| OpenAlex ID | https://openalex.org/A5033798832 |
| ORCID iD | https://orcid.org/0000-0002-8293-1313 |
| Works | 644 |

## Researcher papers

- [B cells and tertiary lymphoid structures promote immunotherapy response](https://scholariq.org/papers/b-cells-and-tertiary-lymphoid-structures-promote-immunotherapy-response/)
- [A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer](https://scholariq.org/papers/a-randomized-trial-of-bevacizumab-an-anti-vascular-endothelial-growth-factor/)
- [Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma](https://scholariq.org/papers/immunologic-and-therapeutic-evaluation-of-a-synthetic-peptide-vaccine-for-the/)
- [Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma](https://scholariq.org/papers/cancer-regression-and-autoimmunity-induced-by-cytotoxic-t-lymphocyte-associated/)
- [A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade](https://scholariq.org/papers/a-cancer-cell-program-promotes-t-cell-exclusion-and-resistance-to-checkpoint/)
- [gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma](https://scholariq.org/papers/gp100-peptide-vaccine-and-interleukin-2-in-patients-with-advanced-melanoma/)
- [Regulation of B Cell Differentiation and Plasma Cell Generation by IL-21, a Novel Inducer of Blimp-1 and Bcl-6](https://scholariq.org/papers/regulation-of-b-cell-differentiation-and-plasma-cell-generation-by-il-21-a-novel/)
- [Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic <i>BRAF</i> -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor](https://scholariq.org/papers/phase-ii-study-of-the-mek1-mek2-inhibitor-trametinib-in-patients-with-metastatic/)
- [Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients](https://scholariq.org/papers/specific-lymphocyte-subsets-predict-response-to-adoptive-cell-therapy-using/)
- [Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy](https://scholariq.org/papers/bempegaldesleukin-selectively-depletes-intratumoral-tregs-and-potentiates-t-cell/)
- [Defining the critical hurdles in cancer immunotherapy](https://scholariq.org/papers/defining-the-critical-hurdles-in-cancer-immunotherapy/)

## Researcher topics

- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Cancer Research and Treatments](https://scholariq.org/topics/cancer-research-and-treatments/)

## Researcher university

- [Moffitt Cancer Center](https://scholariq.org/institutions/moffitt-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.